Growth Ideas

Brief Growth Ideas: MonotaRO (3064 JP): Slow March, Strong 1Q and more

In this briefing:

  1. MonotaRO (3064 JP): Slow March, Strong 1Q
  2. Yaskawa: Results Confirm Bottoming Out Despite Weakness, but the Stock Has Run Too Far
  3. Shenwan Hongyuan (申万宏源) A+H: No Reason for a Valuation Premium
  4. So-Young (新氧) Pre-IPO Review – Au Naturel
  5. Maybe Koito’s Premium Can Be Justified

1. MonotaRO (3064 JP): Slow March, Strong 1Q

Screen%20shot%202019 04 12%20at%207.07.28

MonotaRO’s domestic (parent company) sales growth rate declined in March, but was up in 1Q as a whole. We expect no change to FY Dec-19 guidance when consolidated results are announced at the end of April. 

Parent company data for March show sales up 17.4% year-on-year in nominal terms, but up 23.3% when adjusted for the number of working days in the month. The adjusted figures for January and February were 30.5% and 26.6%. In the three months to March, adjusted sales were up 26.5% vs. 24.2% growth in 4Q of FY Dec-18 and 26.2% a year earlier. 

At ¥2,366 (Thursday, April 11, close), the shares are selling at 51x our estimate for FY Dec-19 and 44x our estimate for FY Dec-20. Price/sales multiples for the same two years are 4.5x and 3.9x. Projected valuations look high, but are on the low side of their recent historical ranges. Continuing double-digit growth should support the share price.

2. Yaskawa: Results Confirm Bottoming Out Despite Weakness, but the Stock Has Run Too Far

Yaskawa%20china%20mc

Yaskawa Electric (6506 JP) reported FY03/19 results yesterday where OP of ¥49.8bn missed guidance of ¥53bn (-6.0% miss) and consensus of ¥52.1bn. Guidance of ¥46.5bn OP for FY02/20 was light relative to consensus at ¥48.7bn and our own expectations for about ¥50bn in OP but we believe guidance looks a little conservative and consider it to be mostly in line. The main concern was 4Q orders which were down 17% YoY and 10% QoQ with both Motion Control and Robotics displaying weakness.

The company also announced a buyback of 0.76% of outstanding shares for ¥9bn which we feel is a little small and also somewhat poorly timed given the 50% rally in the stock price in the last three months.

3. Shenwan Hongyuan (申万宏源) A+H: No Reason for a Valuation Premium

A%20share%20pb%20roe

Shenwan Hongyuan started institutional book building today. We have covered the fundamentals of the company in our previous insight (Shenwan Hongyuan (申万宏源) A+H: A Commoditized Broker Business). In this insight, we will discuss:

  • Valuation comparison with peers
  • A-H premium history of Chinese brokers
  • Key metrics of past Chinese brokers listing in the H-share market
  • Concerns of liquidity

4. So-Young (新氧) Pre-IPO Review – Au Naturel

Contract liabilities indicate healty revenue growth contract liabilities rmbm  chartbuilder

So-Young (SY US) is looking to raise US$150m in its upcoming IPO. The company filed its prospectus with the SEC on Monday.

The company operates online platforms (mobile, website, and WeChat mini program) for discovering, evaluating, and reserving medical aesthetic services in China. It helps medical aesthetic service providers acquire customers through user generated content and other creative content format.

In this insight, we will look at the company’s business model, analyze its financial and operating performance, review the competitive landscape and point out some questions for management.

5. Maybe Koito’s Premium Can Be Justified

2

We mentioned in Koito Outperforms in 3Q While Stanley Disappoints; Latter Still on Track to Achieve FY03/19E Target, that Koito Manufacturing (7276 JP) has managed to beat consensus estimates in 3Q after a series of disappointing results in the previous quarters. This was despite the weak nine-month ended results. The company cited the loss in sales from China (as a result of the deconsolidation of the Shanghai unit) alongside unfavourable economic conditions especially in China and Europe as key reasons for the decline in earnings. Our visit to Koito in March, gave us more insight on the effect of its deconsolidated Shanghai unit and its future plans in China, alongside their investment for capacity expansions and new products. Following these insights, we have revised our view on Koito in a slightly positive manner.

Get Straight to the Source on Smartkarma

Smartkarma supports the world’s leading investors with high-quality, timely, and actionable Insights. Subscribe now for unlimited access, or request a demo below.